Innovation and drone delivery
Addressing healthcare disparities through collaborative innovation and drone delivery
Search
Patient Centricity
Patient Centricity
Our Responsibility
Human Health Our Responsibility
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Brigimadlin (BI 907828)
Brigimadlin BI 907828
CT-155
Digital therapeutic
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
European Commission decision for Pradaxa® in children with VTE
Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age
Microbial expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins, complementing mammalian cell processes for larger proteins like monoclonal antibodies.
the-adventures-of-reggie-the-red-blood-cell_e-book.pdf
Global Network | Bioxcellence | Boehringer Ingelheim
Our network of manufacturing facilities spans the globe, from Fremont, in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China
About Our Business| Bioxcellence | Boehringer Ingelheim
BioXcellence, reliable contract development & manufacturing partner to the pharmaceutical industry. A trusted partner through the Lifecyle of your product.
Contact BioXcellence
Contact BioXcellence
Media & News | Bioxcellence | Boehringer Ingelheim
Stay updated with BioXcellence Media & News. Explore the latest industry trends & news in global biopharmaceutical contract manufacturing. Don't miss out!
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
New digital Tx collab with Click
New digital therapy collaboration with Click Tx
Positive-CHMP-opinion-for-dabigatran-in-children
Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Data Science
Revolutionizing research and development with data driven insights
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia